Leonurine

Developed by Chair Prof. Zhu Yizhun’s research team. After more than 10 years of painstaking research, it has been found that the monomer extracted and chemically synthesized from the colloquially known herb Motherwort, or Leonurus cardiaca (also known as SCM-198), has obvious efficacy on hyperlipidemia, atherosclerosis, cerebral apoplexy, and other diseases. Motherwort has been confirmed to have a significant lipid-lowering effect, which can inhibit the inflammation of atherosclerotic plaques and reduce the area of cerebral cortex infarction caused by cerebral ischemia. It sustains a fast and significant effect on the treatment of acute stroke, bringing good news to middle-aged and elderly patients with cardiovascular and cerebrovascular diseases.

At present, the project has applied for patent protection, has obtained the "drug clinical trial approval" issued by the State Drug Administration, and has been approved to conduct clinical research in the United States through the FDA.